Objective:To evaluate the clinical value of peripheral blood monocyte subset analysis in the diagnosis and treatment of chronic myelomonocytic leukemia (CMML) .Method:We retrospectively enrolled 51 patients newly diagnosed with CMML at Guangdong Provincial People's Hospital between June 1, 2020, and December 31, 2024, according to the WHO 2022 diagnostic criteria. Twenty-three patients with other myeloid neoplasms (excluding CMML) and peripheral monocytosis (absolute count ≥0.5×10 9/L and percentage ≥10%) were included as the control group. All patients underwent bone marrow aspiration for examinations including bone marrow smears, biopsies, cytogenetics, and gene mutation analysis to establish a definitive diagnosis. Concurrently, flow cytometry was used to determine the proportions of peripheral blood monocyte subsets: classical (MO1, CD14 +CD16 -) , intermediate (MO2, CD14 +CD16 +) , and non-classical (MO3, CD14 lowCD16 +) . Differences between the groups were compared, and diagnostic efficacy was evaluated using receiver operating characteristic (ROC) curves. Result:Among the 51 CMML patients, the proportion of the peripheral blood MO1 subset was significantly higher than that in patients with other myeloid neoplasms ( P=0.027) , whereas there were no significant differences in the MO2 and MO3 subsets (all P>0.05) . Further analysis revealed that 43 (84.31%) of the CMML patients met the WHO diagnostic threshold for the MO1 subset (≥94%) , while the remaining 8 patients did not; 46 patients (90.20%) had MO3 subset proportions below the threshold proposed by Hudson (≤1.13%) , while the remaining 5 patients were above this threshold. In-depth analysis showed that among the 8 patients who did not meet the WHO criteria, 7 were experiencing inflammation. Similarly, all 5 patients who did not meet the Hudson criteria were in an inflammatory state. Subsequent ROC curve analysis of this cohort identified a cut-off value for the MO1 subset of 97.55% [Area Under the Curve (AUC) =0.661, P=0.027], which aligns with the WHO criteria. Conclusion:Peripheral blood monocyte subset analysis, particularly MO1 subset analysis, can effectively assist in CMML diagnosis, but exclusion of inflammatory conditions is required.

Objective:To evaluate the clinical value of peripheral blood monocyte subset analysis in the diagnosis and treatment of chronic myelomonocytic leukemia (CMML) .Method:We retrospectively enrolled 51 patients newly diagnosed with CMML at Guangdong Provincial People's Hospital between June 1, 2020, and December 31, 2024, according to the WHO 2022 diagnostic criteria. Twenty-three patients with other myeloid neoplasms (excluding CMML) and peripheral monocytosis (absolute count ≥0.5×10 9/L and percentage ≥10%) were included as the control group. All patients underwent bone marrow aspiration for examinations including bone marrow smears, biopsies, cytogenetics, and gene mutation analysis to establish a definitive diagnosis. Concurrently, flow cytometry was used to determine the proportions of peripheral blood monocyte subsets: classical (MO1, CD14 +CD16 -) , intermediate (MO2, CD14 +CD16 +) , and non-classical (MO3, CD14 lowCD16 +) . Differences between the groups were compared, and diagnostic efficacy was evaluated using receiver operating characteristic (ROC) curves. Result:Among the 51 CMML patients, the proportion of the peripheral blood MO1 subset was significantly higher than that in patients with other myeloid neoplasms ( P=0.027) , whereas there were no significant differences in the MO2 and MO3 subsets (all P>0.05) . Further analysis revealed that 43 (84.31%) of the CMML patients met the WHO diagnostic threshold for the MO1 subset (≥94%) , while the remaining 8 patients did not; 46 patients (90.20%) had MO3 subset proportions below the threshold proposed by Hudson (≤1.13%) , while the remaining 5 patients were above this threshold. In-depth analysis showed that among the 8 patients who did not meet the WHO criteria, 7 were experiencing inflammation. Similarly, all 5 patients who did not meet the Hudson criteria were in an inflammatory state. Subsequent ROC curve analysis of this cohort identified a cut-off value for the MO1 subset of 97.55% [Area Under the Curve (AUC) =0.661, P=0.027], which aligns with the WHO criteria. Conclusion:Peripheral blood monocyte subset analysis, particularly MO1 subset analysis, can effectively assist in CMML diagnosis, but exclusion of inflammatory conditions is required.

Objective To explore the application of PDCA cycle management mode in public health emergencies in gen-eral hospitals.Methods The PDCA cycle management model was carried out.35 medical workers from Shawan People's Hos-pital of Panyu District,Guangzhou from January 2021 to December 2022 were included as research objects and divided according to different time points as cut-off points.The PDCA cycle management model was not implemented from January to December 2021.The PDCA cycle mode management will be implemented from January to December 2022.The treatment time,job burnout and emergency response ability of medical staff before and after PDCA cycle management were compared.Results After the im-plementation of PDCA cycle mode management,the pre-hospital examination,hospital admission,symptom examination and dis-ease diagnosis of medical staff were less than those before the implementation of PDCA cycle mode management,and the differ-ence was significant(P＜0.05).After the implementation of PDCA cycle mode management,the scores of emotional consump-tion and deindividuation tendency of medical staff were lower than those before the implementation of PDCA cycle mode manage-ment,while the scores of low sense of accomplishment after the implementation of PDCA cycle mode management were higher than those before the implementation of PDCA cycle mode management,with significant differences(P＜0.05).After the imple-mentation of PDCA cycle mode management,the emergency ability scores of medical staff were higher than those before the imple-mentation of PDCA cycle mode management,and the difference was significant(P＜0.05).Conclusion PDCA cycle manage-ment mode has a good application effect in public health emergencies in general hospitals,which is conducive to more efficient and successful treatment of public health emergencies.

Drug-device combination product, which comprises at least a drug and a medical device, has been proved to effectively reduce the risk of complications accompanied with conventional medical devices implantation, and has a great clinical success especially in implantable therapeutics. Herein, we firstly elaborated the definitions and requirements of drug-device combination product in different countries, then summarized the market application and research development of typical drug-device combination products. Technical problems and the trend of future development had also been analyzed.
Drug Delivery Systems/instrumentation* ; Equipment Design ; Prostheses and Implants

Objective To evaluate the value of semi-quantitative parameters of dynamic contrast-enhanced MRI (DCE-MRI)in predicting and monitoring therapeutic efficacy of concurrent chemoradiotherapy in laryngeal and hypopharyngeal carcinoma.Methods Forty-four patients with pathologically confirmed laryngeal and hypopharyngeal squamous cell carcinoma were collected.Time signal intensity curves (TIC)and related semi-quantitative parameters were obtained before (point 1 ),during (point 2)and after (point 3 )treatment. Tumor remission were assessed at the end of treatment and the statistical analyses were performed using SPSS.Results Twenty two patients had a complete remission as CR group and 22 had a partial remission as PR group.The parameters of time to peak (TTP), maximum signal enhancement ratio (SERmax ),positive enhancement integral (PEI),SER70 and SER84 at point 1 were higher than those at point 2,and there were significant differences between two groups (P <0.05).The values of SERmax ,SER42 ,SER56 ,SER70 and SER84 before treatment were higher in CR group than those in PR group,exhibiting significant differences between two groups (P <0.05).ROC curve analysis showed the threshold for SER56 was set to ≥129.4％ to predict complete remission,and the sensitivity and specificity were 60％ and 86.4％,respectively.Comparison of remission rates among different types of TIC showed complete remission rates in typeⅠTIC and type Ⅲ TIC were 87.5％ and 39.3％,respectively,exhibiting a significant difference between two groups (P =0.041). Conclusion TIC types and semi-quantitative parameters of DCE-MRI can predict therapeutic efficacy of concurrent chemoradiotherapy in laryngeal and hypopharyngeal carcinoma,SER56 is the most important predictive semi-quantitative parameter,and prognosis is much better in typeⅠTIC than type Ⅲ TIC before treatment.